Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences
-
New Directions in Biology and Disease of
Skeletal Muscle Conference to be heldJune 25 –June 28, 2018 inNew Orleans, LA , atThe Westin New Orleans Canal Place .Andrew Nichols , Ph.D., Chief Scientific Officer of Catabasis, will give an oral presentation titled “Edasalonexent, an NF-kB Inhibitor in Development as a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy” onMonday, June 25, 2018 , from3:10pm –3:40pm ET in theGrand Ballroom on the 12th floor.
-
2018 PPMD Annual
Connect Conference to be heldJune 28 –June 30, 2018 inScottsdale, AZ , at The Phoenician.Joanne Donovan , M.D., Ph.D., Chief Medical Officer of Catabasis, will present “MoveDMD: Phase 2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy” during the poster session onThursday, June 28, 2018 , at6:30pm MST and an oral presentation onFriday, June 29, 2018 , from2:20pm-2:40pm MST .
-
15th
International Congress on Neuromuscular Diseases to be heldJuly 6 –July 10, 2018 inVienna, Austria , at the Hilton Vienna Am Stadtpark.Joanne Donovan , M.D., Ph.D., Chief Medical Officer of Catabasis, will present “Rationale for Edasalonexent Dose Schedule in Phase 2 of the MoveDMD Trial” during the poster session onSaturday, July 7, 2018 , from 17:15 –18:30 CEST in the Exhibit Hall.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is
an investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a
protein that is activated in DMD and drives inflammation, fibrosis and
muscle degeneration and suppresses muscle regeneration. Edasalonexent
continues to be dosed in an open-label extension of the MoveDMD Phase 2
clinical trial, and Catabasis is preparing for a single global Phase 3
trial to evaluate the efficacy and safety of edasalonexent for
registration purposes, dependent on raising capital. The
About Catabasis
At
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005026/en/
Source:
Investor and Media Contact
Catabasis
Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com